How Does Avanos Company Reach Customers and Turn Demand into Sales?

Avanos prioritizes Interventional Pain Specialists and Orthopedic Surgeons who perform ambulatory procedures; ASCs accounted for a growing share of interventional procedure volume in 2025, driving demand for opioid-sparing recovery tools that shorten length of stay and improve throughput.

Gastroenterologists and Neonatologists are targeted for enteral feeding solutions that enable home-based nutrition; Avanos emphasizes devices that reduce complications and readmissions, key metrics tied to reimbursement and clinician preference.

Hospital VACs and supply chain teams evaluate total cost of care; Avanos targets these buyers with data on reduced opioid use, shorter stays, and lower readmission rates to secure formulary placement and bulk contracts.

Avanos positions products as clinically validated, cost-effective tools that support fast-track recovery and safe home transitions; messaging ties device performance to metrics VACs care about: length of stay, complication rates, and cost per case.

Focusing on ASCs and clinicians prioritizing fast recovery captures growth where interventional volume rose in 2025; by quantifying improvements in discharge times and opioid reduction, Avanos converts clinical preference into procurement wins and recurring revenue. See related analysis in How Avanos Company Works and Makes Money.

Targeting clinicians and VACs shortens sales cycles: clinical champions drive adoption, VAC endorsement scales purchasing. Avanos blends direct field sales, distributor partnerships, and value dossiers to lower customer acquisition cost and convert demand into sales across ASCs, hospitals, and home-health channels.

Direct, field-led selling to hospitals and clinics drives capital-equipment placements; consumables follow via contracts and purchase orders. Distributor partnerships supplement reach in select international markets, balancing Avanos customer acquisition across channels.

One-time revenue from devices (radiofrequency generators, capital equipment) is monetized by recurring sales of disposables and consumables – about 80% of Digestive Health revenue from consumables – creating stable, high-margin annuity streams.

Clinical superiority, peer-reviewed evidence, and on-site nursing support convert trials into procurement. Sales execution focuses on pilot cases, hospital formulary inclusion, and ROI data – radiofrequency generator placements drive downstream probe volume and adoption.

Recurring consumable demand and consumable attach rates secure repeat revenue; the 2025 Trident Health integration enabled cross-selling of interventional products into orthopedic accounts, expanding average revenue per account and retention.

Growth is underpinned by an aging population and hospital shifts to non-opioid protocols, supporting sustained device uptake; Avanos customer acquisition benefits from entrenched clinical relationships and product-market fit for pain-management devices.

Avanos leverages a hybrid go-to-market: direct field sales into hospitals and clinics plus select distributor partners, with CRM-driven Avanos demand generation and targeted digital marketing for healthcare products; trade show ROI and clinician education programs remain core to converting leads to sales.

Key risks: intensified competition in surgical pain pumps, price pressure from group purchasing organizations, potential reimbursement cuts, and any slowdown in hospital elective procedures that would reduce near-term device volume; Avanos pricing strategy for medical devices must remain competitive.

Outlook for 2025/2026 is constructive: management reports an adjusted EBITDA margin around 21 percent for 2025 and projects a path to over $100 million in free cash flow, reflecting de-risked balance sheet and lean operating model; commercial focus on high-growth medtech categories should keep Avanos sales strategy and Avanos marketing strategy effective.